Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 3,107 | 393 | 2,685 |
| Samples | 363 | 80 | 278 |
| Peptides | 355 | 69 | 295 |
Function
TP73 · Tumor protein p73
This gene encodes a member of the p53 family of transcription factors involved in cellular responses to stress and development. It maps to a region on chromosome 1p36 that is frequently deleted in neuroblastoma and other tumors, and thought to contain multiple tumor suppressor genes. The demonstration that this gene is monoallelically expressed (likely from the maternal allele), supports the notion that it is a candidate gene for neuroblastoma. Many transcript variants resulting from alternative splicing and/or use of alternate promoters have been found for this gene, but the biological validity and the full-length nature of some variants have not been determined. [provided by RefSeq, Feb 2011].
Isoforms & Proteins
11 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000378295 | O15350 | 368 | 261 |
| ENST00000378288 | O15350-8 | 301 | 224 |
| ENST00000357733 | O15350-5 | 298 | 223 |
| ENST00000603362 | O15350-5 | 298 | 223 |
| ENST00000378290 | O15350-11 | 291 | 216 |
| ENST00000346387 | O15350-6 | 281 | 211 |
| ENST00000604479 | O15350-6 | 281 | 211 |
| ENST00000354437 | O15350-2 | 272 | 198 |
| ENST00000378285 | O15350-9 | 249 | 179 |
| ENST00000378280 | O15350-10 | 239 | 175 |
| ENST00000604074 | O15350-4 | 229 | 166 |
Gene Properties
Recurrent Mutations
All 261 amino-acid changes on canonical ENST00000378295 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in TP73 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in TP73 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Endometrial Carcinoma | 9/42 21% | 21/612 3% |
| Glioblastoma | 4/98 4% | 0/0 0% |
| Hodgkins Lymphoma | 2/16 12% | 3/122 2% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Gastric Carcinoma | 7/74 9% | 27/1809 1% |
| Cervical Carcinoma | 0/35 0% | 8/422 2% |
| Melanoma | 2/210 1% | 33/1899 2% |
| Colorectal Carcinoma | 8/143 6% | 45/3239 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 10/752 1% |
| Non-Small Cell Lung Carcinoma | 10/304 3% | 11/1390 1% |
| Neuroendocrine Tumour | 7/154 5% | 2/577 0% |
| Chondrosarcoma | 1/14 7% | 0/75 0% |
| Other Solid Cancers | 0/94 0% | 16/1515 1% |
| Bladder Carcinoma | 2/58 3% | 7/956 1% |
| Hepatocellular Carcinoma | 0/46 0% | 17/2210 1% |
| Thyroid Gland Carcinoma | 2/45 4% | 8/1592 0% |
| Non-Cancerous | 0/104 0% | 5/830 1% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| B-Cell Non-Hodgkins Lymphoma | 6/88 7% | 7/2534 0% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Glioma | 0/52 0% | 10/2127 0% |
| Biliary Tract Carcinoma | 0/54 0% | 4/950 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 10/2550 0% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 1/810 0% |
| Ewings Sarcoma | 1/63 2% | 0/262 0% |
| Breast Carcinoma | 2/144 1% | 8/3264 0% |
| Other Blood Cancers | 1/61 2% | 7/2725 0% |
Mutation Distribution
Where TP73 is mutated · all tissues, split by cell line vs tissue
How many mutations in TP73 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 3,107 mutations in TP73
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|